Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study

Beitrag in einer Fachzeitschrift


Details zur Publikation

Autorinnen und Autoren: Govers TM, Hessels D, Vlaeminck-Guillem V, Schmitz-Draeger BJ, Stief CG, Martinez-Ballesteros C, Ferro M, Borque-Fernando A, Rubio-Briones J, Sedelaarll JPM, Van Criekinge W, Schalken JA
Zeitschrift: Prostate Cancer and Prostatic Diseases
Jahr der Veröffentlichung: 2019
Band: 22
Heftnummer: 1
Seitenbereich: 101-109
ISSN: 1365-7852


Abstract

Background Low specificity of prostate-specific antigen results in a considerable number of unnecessary prostate biopsies in current practice. SelectMDx (R) predicts significant prostate cancer upon biopsy and is used to reduce the number of unnecessary initial prostate biopsies. Furthermore, potential overtreatment of insignificant prostate cancer can be reduced. Besides the diagnostic accuracy of the test, also the context in a specific country determines the potential health benefit and cost-effectiveness. Therefore, the health benefit and cost-effectiveness of SelectMDx were assessed in France, Germany, Italy, and Spain.


Einrichtungen weiterer Autorinnen und Autoren

European Institute of Oncology / Istituto Europeo di Oncologia (IEO)
Hospices Civils de Lyon (CHU)
Hospital Universitario Miguel Servet
Hospital Universitario Puerta de Hierro - Majadahonda
Ludwig-Maximilians-Universität (LMU)
MDxHealth Netherlands
MedValue
Radboud University Nijmegen Medical Centre / Radboudumc of voluit Radboud Universitair Medisch Centrum (UMC)
Universiteit Gent (UGent) / Ghent University
Valencia Oncology Institute Foundation / Fundación Instituto Valenciano de Oncología (IVO)


Zitierweisen

APA:
Govers, T.M., Hessels, D., Vlaeminck-Guillem, V., Schmitz-Draeger, B.J., Stief, C.G., Martinez-Ballesteros, C.,... Schalken, J.A. (2019). Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study. Prostate Cancer and Prostatic Diseases, 22(1), 101-109. https://dx.doi.org/10.1038/s41391-018-0076-3

MLA:
Govers, Tim M., et al. "Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study." Prostate Cancer and Prostatic Diseases 22.1 (2019): 101-109.

BibTeX: 

Zuletzt aktualisiert 2019-13-03 um 18:23